{
    "body": "Which is the prognostic meaning of delayed enhancement documented in patients hypertrophic cardiomyopathy?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19740409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23376948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22128204", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19784900", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20688032", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18204915", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22135401", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12224720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19808288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18562248", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22498326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22348519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21234292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15861263", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21498307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20339815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19474054", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22687593", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20079992", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20667520", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20102955", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18208827", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19477402", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22935464"
    ], 
    "ideal_answer": [
        "Delayed enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients, and is associated with cardiovascular mortality, heart failure death, and all-cause mortality in HCM."
    ], 
    "exact_answer": [
        "Delayed enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011379", 
        "http://www.disease-ontology.org/api/metadata/DOID:11984", 
        "http://www.disease-ontology.org/api/metadata/DOID:11986", 
        "http://www.disease-ontology.org/api/metadata/DOID:0050700", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009682", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024741", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002312"
    ], 
    "type": "factoid", 
    "id": "5339ecf4d6d3ac6a3400005f", 
    "snippets": [
        {
            "offsetInBeginSection": 1208, 
            "offsetInEndSection": 1466, 
            "text": " It is possible to conclude that there is a high prevalence of myocardial fibrosis in hypertrophic cardiomyopathy patients with high-risk or recovered from cardiac sudden death, like those with clinical indication to implantable cardioverter -defibrillator. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20339815", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 927, 
            "offsetInEndSection": 1018, 
            "text": "AF in HCM is related with myocardial fibrosis detected by DE-CMR and dilatation of the LA. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20079992", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1183, 
            "offsetInEndSection": 1388, 
            "text": "Over the follow-up period, the annualized adverse cardiovascular event rate in patients with DE exceeded that in patients without DE but did not achieve statistical significance (5.5% versus 3.3%; P=0.5). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1452, 
            "offsetInEndSection": 1780, 
            "text": "Late gadolinium enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients. There are significant relationships between LGE and cardiovascular mortality, heart failure death, and all-cause mortality in HCM. Additionally, LGE and SCD/aborted SCD displayed a trend toward significance. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22498326", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1185, 
            "offsetInEndSection": 1364, 
            "text": "The hyperenhanced apical myocardium had a lower percentage of systolic myocardial thickening, and was associated with serious symptoms (e.g. syncope) and ventricular arrhythmias. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498307", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1221, 
            "offsetInEndSection": 1413, 
            "text": "A semi-quantitative index of DCE is a significant multivariable predictor of both clinical VT/VF and of risk for SCD and may contribute to risk assessment in borderline or controversial cases.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19474054", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1419, 
            "offsetInEndSection": 1509, 
            "text": "Myocardial scar imaged by CE-CMR is common in patients with HCM, and is predictive of VT. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18562248", 
            "endSection": "abstract"
        }
    ]
}